Ana Velázquez Mañana, Assistant Professor of Medicine at the University of California, San Francisco, shared a post on X:
”As you build your schedule for ASCO26, don’t miss (or bookmark to watch later) several interesting Lung Cancer abstracts being presented outside the lung cancer tracks.
Some highlights include:
- ctDNA Clinical Science Symposium:
FLAME: osimertinib ± chemotherapy in EGFRm NSCLC with persistent ctDNA+ after 3 weeks on 1L osimertinib - Global Onc, Care Delivery: Clinical Science Symposium: Low-dose pembrolizumab + chemotherapy in 1L advanced NSCLC
- CNS Tumors Oral Abstracts: ESAONA: asandeutertinib vs. osimertinib in 1L EGFRm NSCLC with brain metastases.”
Other Articles Featuring Ana Velázquez Mañana on OncoDaily.